| Pan-cancer analysis of whole genomes The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Nature 578 (7793), 82, 2020 | 2989* | 2020 |
| The evolutionary history of 2,658 cancers M Gerstung, C Jolly, I Leshchiner, SC Dentro, SG Rosado, D Rosebrock, ... Nature, 122–128, 2020 | 1208 | 2020 |
| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 942 | 2019 |
| Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes SC Dentro, I Leshchiner, K Haase, M Tarabichi, J Wintersinger, ... Cell 184 (8), 2239-2254. e39, 2021 | 559 | 2021 |
| Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition B Rodriguez-Martin, EG Alvarez, A Baez-Ortega, J Zamora, F Supek, ... Nature genetics 52 (3), 306-319, 2020 | 503 | 2020 |
| Pervasive chromosomal instability and karyotype order in tumour evolution TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ... Nature 587 (7832), 126-132, 2020 | 391 | 2020 |
| Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization F Christ, S Shaw, J Demeulemeester, BA Desimmie, A Marchand, S Butler, ... Antimicrobial agents and chemotherapy 56 (8), 4365-4374, 2012 | 234 | 2012 |
| The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites J De Rijck, C de Kogel, J Demeulemeester, S Vets, S El Ashkar, N Malani, ... Cell reports 5 (4), 886-894, 2013 | 203 | 2013 |
| Genomic–transcriptomic evolution in lung cancer and metastasis C Martínez-Ruiz, JRM Black, C Puttick, MS Hill, J Demeulemeester, ... Nature 616 (7957), 543-552, 2023 | 195 | 2023 |
| LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions BA Desimmie, R Schrijvers, J Demeulemeester, D Borrenberghs, ... Retrovirology 10 (1), 57, 2013 | 188 | 2013 |
| LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs R Schrijvers, J De Rijck, J Demeulemeester, N Adachi, S Vets, K Ronen, ... PLoS pathogens 8 (3), e1002558, 2012 | 163 | 2012 |
| Recurrent rearrangements of FOS and FOSB define osteoblastoma MW Fittall, W Mifsud, N Pillay, H Ye, AC Strobl, A Verfaillie, ... Nature communications 9 (1), 2150, 2018 | 149 | 2018 |
| Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma O Marin-Bejar, A Rogiers, M Dewaele, J Femel, P Karras, J Pozniak, ... Cancer cell 39 (8), 1135-1149. e8, 2021 | 145 | 2021 |
| LEDGIN-mediated inhibition of integrase–LEDGF/p75 interaction reduces reactivation of residual latent HIV LS Vranckx, J Demeulemeester, S Saleh, A Boll, G Vansant, R Schrijvers, ... EBioMedicine 8, 248-264, 2016 | 130 | 2016 |
| Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors J Cheng, J Demeulemeester, DC Wedge, HKM Vollan, JJ Pitt, ... Nature communications 8 (1), 1221, 2017 | 115 | 2017 |
| Retroviral integration: site matters: mechanisms and consequences of retroviral integration site selection J Demeulemeester, J De Rijck, R Gijsbers, Z Debyser Bioessays 37 (11), 1202-1214, 2015 | 104 | 2015 |
| Evolutionary characterization of lung adenocarcinoma morphology in TRACERx T Karasaki, DA Moore, S Veeriah, C Naceur-Lombardelli, A Toncheva, ... Nature medicine 29 (4), 833-845, 2023 | 99 | 2023 |
| System-wide mapping of peptide-GPCR interactions in C. elegans I Beets, S Zels, E Vandewyer, J Demeulemeester, J Caers, E Baytemur, ... Cell reports 42 (9), 2023 | 97 | 2023 |
| Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing J Demeulemeester, P Kumar, EK Møller, S Nord, DC Wedge, A Peterson, ... Genome biology 17 (1), 250, 2016 | 95 | 2016 |
| LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006–2014) J Demeulemeester, P Chaltin, A Marchand, M De Maeyer, Z Debyser, ... Expert opinion on therapeutic patents 24 (6), 609-632, 2014 | 94 | 2014 |
zeger debyserKU LeuvenVerified email at med.kuleuven.be
